A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate“ (VISION)

25.09.2015 bis 31.07.2017

Dimethyl fumarate is the first oral first-line MS-therapy assumed to have protective effects on neuronal cells. It is for example able to promote cytoprotective responses in cells by activating the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway.
By crossing the brain-blood-barrier, it is supposed that dimethyl fumarate might also have an effect on the ocular fundus and might therefore protect retinal ganglion cells and their axons from degeneration, irrespective of an acute optic neuritis in the initial MS phase.
This trial is performed to evaluate the neuroprotective effect of dimethyl fumarate in RRMS patients in an early phase.